Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRVS
CRVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRVS News
Adams Street Partners Exits Entire Paymentus Stake for $5.9 Million
May 24 2026
Yahoo Finance
Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
May 17 2026
Fool
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
May 17 2026
Yahoo Finance
Corvus Pharmaceuticals Shares Drop After Phase 1 Trial Data Release
May 14 2026
seekingalpha
Corvus Pharmaceuticals Appoints New Board Member
Apr 23 2026
Newsfilter
Corvus Pharmaceuticals Unveils New Drug Data at SID Meeting
Apr 21 2026
Newsfilter
Corvus' Oral Therapy Potential Underestimated by Analysts
Apr 17 2026
stocktwits
Goldman Sachs Initiates Buy on Corvus with $40 Target
Apr 17 2026
seekingalpha
Goldman Sachs Bullish on Corvus Pharmaceuticals Stock Outlook
Apr 17 2026
CNBC
Latest Ratings and Outlook from Wall Street
Apr 17 2026
CNBC
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Mar 13 2026
moomoo
Corvus (CRVS) Q4 2025 Earnings Call Transcript
Mar 13 2026
NASDAQ.COM
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
Mar 13 2026
seekingalpha
Corvus Pharmaceuticals Q4 Earnings Miss Expectations
Mar 12 2026
seekingalpha
Corvus Pharmaceuticals Set to Announce Q4 Earnings on March 11
Mar 11 2026
seekingalpha
Analysis of Corvus Pharmaceuticals Put Selling
Feb 02 2026
NASDAQ.COM
Show More News
